- Home
- ADI vs NVO Comparison
ADI vs NVO Comparison
Compare ADI & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADI | NVO |
|---|---|---|
| Founded | 1965 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.5B | 199.4B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ADI | NVO |
|---|---|---|
| Price | $391.82 | $40.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 34 | 14 |
| Target Price | ★ $472.44 | $46.03 |
| AVG Volume (30 Days) | 4.4M | ★ 8.8M |
| Earning Date | 11-24-2026 | 11-04-2026 |
| Dividend Yield | 1.11% | ★ 3.10% |
| EPS Growth | ★ 39.02 | N/A |
| EPS | ★ 6.83 | N/A |
| Revenue | ★ $6,200,942,000.00 | N/A |
| Revenue This Year | $37.26 | N/A |
| Revenue Next Year | $21.59 | $1.30 |
| P/E Ratio | $57.90 | ★ $13.60 |
| Revenue Growth | ★ 21.41 | N/A |
| 52 Week Low | $224.25 | $35.12 |
| 52 Week High | $449.52 | $64.16 |
Technical Indicators
Market Signals| Indicator | ADI | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 52.77 |
| Support Level | $382.18 | $37.61 |
| Resistance Level | $407.17 | $41.41 |
| Average True Range (ATR) | 19.04 | 0.72 |
| MACD | -4.04 | 0.32 |
| Stochastic Oscillator | 48.04 | 49.15 |
Price Performance
Historical ComparisonAbout ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.